Upside | ||||||
|---|---|---|---|---|---|---|
| BSX | 4.50% | aa.aa | 97.64 | -0.75% | 29,735 | |
| ARGX | 4.10% | aa.aa | 788.49 | -0.89% | 3,053 | |
| ALNY | 3.88% | aa.aa | 398.29 | -0.28% | 6,060 | |
| UCB | 3.64% | aa.aa | 254.80 | +0.91% | 8,299 | |
| DHR | 3.60% | aa.aa | 238.37 | +1.43% | 9,778 | |
| COGT | 3.48% | aa.aa | 35.350 | -0.62% | 62,698 | |
| ISRG | 3.05% | aa.aa | 586.24 | +0.20% | 3,399 | |
| PEN | 2.95% | aa.aa | 322.44 | +2.19% | 5,964 | |
| PODD | 2.88% | aa.aa | 289.04 | -1.31% | 6,372 | |
| VEEV | 2.79% | aa.aa | 240.12 | -0.43% | 7,941 |
Fidelity Covington Trust - Fidelity Disruptive Medicine ETF is an exchange traded fund launched and managed by Fidelity Management & Research Company LLC. It is co-managed by FMR Investment Management (UK) Limited, Fidelity Management & Research (Hong Kong) Limited and Fidelity Management & Research (Japan) Limited. It invests in public equity markets of global region. It invests in stocks of companies operating across health care, health care equipment and services, health care equipment and medical equipment sectors. The fund invests in growth and value stocks of companies across diversified market capitalization. It employs fundamental and quantitative analysis with bottom-up stock picking approach to create its portfolio. The fund seeks to benchmark the performance of its portfolio against the MSCI ACWI (All Country World Index) Index and the MSCI All Country World Healthcare Equal Weighted Index. Fidelity Covington Trust - Fidelity Disruptive Medicine ETF was formed on April 16, 2020 and is domiciled in the United States.